Company intelligence / Profile preview

Kadmon

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Rezurock™ (belumosudil), a first-in-class oral ROCK2 inhibitor, received FDA approval in July 2021 for chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy. Clinical trials showed a response rate of ~75% with durable benefit. Other pipeline assets include candidates for fibrotic and immune diseases as well as immuno-oncology therapies. The company was acquired by Sanofi in November 2021 and its stock delisted from NASDAQ.[3][6]

Therapeutic areas: PulmonologyCardiovascularMetabolic DisordersRheumatologyImmunologyOncologyInfectious Diseases
Modalities: Small molecules[10]Antibodies[10]Antibody fusion proteins[10]Interferons[10]
Industry: Biotech

Partnerships

– BioNova Pharma for KD025/belumosudil development/commercialization in China [5]– Various academic collaborations historically; specifics not detailed in current sources.

Beyond the preview

Go deeper on Kadmon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kadmon.